Immunotech Laboratories Stock (OTC: IMMB)

Immunotech Laboratories (OTC:IMMB) Stock, Quote.Headers.trade-ideas

Immunotech Laboratories Inc. is an organization with full indefinite licensing rights of the Irreversible Pepsin Fraction peptide molecule for the specific treatment and preventing of the HIV/AIDS indication.

News

Intraday Update

Markets

Movers

Trading Ideas

ALLE

AMKR

AMRR

ATBPF

ATEC

BDSI

BEVVF

BPYPP

BUKS

CODI

CROX

CWTC

CXKJ

DOOR

EPIX

FITBO

FLOW

FMBV

GNBT

GPIW

GRMN

HURN

IMXI

IPHI

ISEE

KBLM

KFRC

MFSF

MGRC

NBTB

NSIT

NUAN

PDFS

PRFT

PSMT

QALB

QCRH

RDCM

REPH

RETA

REXR

RLBY

RPAI

SHOO

SITC

SITE

SLGX

TMEB

TRNS

TRRSF

VNWTF

VRTX

WTBA

SLFYF

ELEEF

CMCL

FBAYF

IMMB

Stocks That Hit 52-Week Highs On Wednesday

IMMUNOTECH LABS INC by Immunotech Laboratories, Inc.

Immunotech Laboratories Inc

Immix Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMX#NASDAQ">IMMX</a>) (&quot;ImmixBio&quot;, &quot;Company&quot;, &quot;We&quot; or &quot;Us&quot;), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)&trade;&nbsp;targeting oncology and immuno-dysregulated diseases, today announced that Chief Executive Officer Ilya Rachman, MD, PhD, and Chief Financial Officer Gabriel Morris will present a company overview and milestones achieved to enable kick-off of 2 IMX-110 clinical trials at the ThinkEquity Conference at the Mandarin Oriental Hotel in New York, New York on Wednesday, October 26, 2022 at 2:00 PM ET. 
&nbsp;
<ul>
<li>Presentation date and time: October 26, 2022, 2:00 PM ET</li>
<li>View the live presentation:&nbsp;<a href="http://www.immixbio.com/thinkequity2022">http://www.immixbio.com/thinkequity2022</a></li>
<li>Presentation Topic: ImmixBio Milestones Achieved to Enable Kick-off of 2 IMX-110 Clinical Trials 
	&nbsp;</li>
</ul>
A live webcast of the presentation will be available on the Events &amp; Presentations page located within the Investor Relations section of the ImmixBio website at&nbsp;<a href="http://www.immixbio.com/IR">http://www.immixbio.com/IR</a>&nbsp;for approximately 90 days following the presentation.
&quot;I am pleased with the level of investor interest in Immix Biopharma after we announced in October that IMX-110 clinical trial data is expected to be released on a rolling basis beginning in&nbsp;Q1&nbsp;2023,&quot; said Ilya Rachman, MD, PhD. &quot;Since then, we have fielded additional inbound industry interest in ImmixBio. We are especially excited about our upcoming combination trial of IMX-110 with BeiGene / Novartis&#39; anti-PD-1, tislelizumab. I am looking forward to presenting milestones we have achieved to enable kick-off of 2 IMX-110 clinical trials at the upcoming ThinkEquity conference.&quot;

Events

IMMX

Immix Biopharma To Present Milestones Achieved To Enable Kick-Off Of 2 IMX-110 Clinical Trials At 2022 ThinkEquity Conference On October 26

Companies have ongoing collaboration in first-line metastatic triple-negative breast cancer
Immunomedics also announces Phase 2 NeoSTAR study in neoadjuvant triple-negative breast cancer has begun patient enrollment 
MORRIS PLAINS, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=WXr7u_xtVLa6vCCfIDOUOnMlKMQLF2LaAidDqaahdc5oS4pdFFD-JdGFMfMoPHYTDY49dPZ0vrNb0lwjaOLCrWMfxQVFU7heks4wYh9e2K0=" target="_blank">Immunomedics, Inc.</a> (NASDAQ:<a class="ticker" href="/stock/IMMU#NASDAQ">IMMU</a>) (&ldquo;Immunomedics&rdquo; or the &ldquo;Company&rdquo;), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced an extension of its current clinical collaboration with Roche to evaluate Trodelvy, Immunomedics&rsquo; anti-Trop-2 ADC, in combination with Tecentriq, Roche&rsquo;s programmed cell death ligand 1 (PD-L1)-blocking checkpoint inhibitor (CPI), in patients with metastatic urothelial cancer (mUC) and metastatic non-small cell lung cancer (mNSCLC).
&ldquo;Given that Trodelvy can cause tumor-cell death with possible neoantigen release, combining it with an immune-stimulating agent, such as atezolizumab, could potentially create a synergistic effect, which can lead to a promising therapeutic option,&rdquo; said Dr. Loretta M. Itri, Chief Medical Officer of Immunomedics.
Under the terms of the extension, Roche will be conducting two open-label, multicenter, randomized Phase 1b/2 studies using its MORPHEUS platform. The MORPHEUS-mUC study will randomize CPI-na&iuml;ve mUC patients who have failed platinum-containing chemotherapy to receive the Tecentriq plus Trodelvy combination or Tecentriq alone. The second study, Morpheus-Lung, will enroll CPI-experienced mNSCLC patients after failure with platinum-based regimen to receive either Tecentriq and Trodelvy or docetaxel alone.
&ldquo;We are pleased to be expanding our partnership with Roche, a global leader in cancer therapy,&rdquo; commented Dr. Behzad Aghazadeh, Executive Chairman of Immunomedics. &ldquo;We believe these combination studies will build a strong foundation for early-line cancer treatment developments.&rdquo;
Separately, Immunomedics also announces that the new Phase 2 NeoSTAR study initiated by Dr. Aditya Bardia at Mass General Cancer Center has enrolled the first patient with localized triple-negative breast cancer to receive Trodelvy before surgery to remove the tumor. Pathological complete response rate is the primary endpoint of this study, with disease-free survival and overall survival serving as secondary endpoints.

Biotech

General

IMMU

RHHBY

Immunomedics Expands Collaboration With Roche Evaluating Trodelvy In Combination With Tecentriq Into Urothelial And Non-Small Cell Lung Cancers

Rumors

Hearing Guggenheim Says Immunomedics Likely Buyers Are Merck, Lilly Or Roche; Says M&A Value May Be $55-$60 Per Share

Immunotech Announces Succesful Completion of Phase I & II Field trials 

Immunotech Laboratories Rises 83,000%

Immunotech Laboratories

Comments

Immunotech Laboratories

Immunotech Laboratories (IMMB) Forecast

Immunotech Laboratories (OTC:IMMB) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga